Mounjaro® vs compounded tirzepatide cost
A cost-focused comparison of brand-name Mounjaro and compounded tirzepatide, including the off-label-for-weight consideration.
Mounjaro® vs compounded tirzepatide — cost
Mounjaro is FDA-approved for type 2 diabetes (used off-label for weight). It has no dedicated self-pay program, so cash-pay leans on retail and GoodRx.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| Compounded (NexLife, flat) | Compounded | $186/mo* | Not FDA-approved |
| Mounjaro® + GoodRx | Brand (T2D) | $900–$1,060/mo | FDA-approved |
| Mounjaro® retail list | Brand (T2D) | $1,069–$1,080/mo | FDA-approved |
| Zepbound® self-pay (same molecule, weight) | Brand | $299–$449/mo | FDA-approved |
For weight management specifically, Zepbound self-pay or compounded are usually cheaper than cash-pay Mounjaro. Verified June 2026.
Which is cheaper — and the off-label note
On cash cost, flat-rate compounded ($186/mo) is well below Mounjaro retail (~$1,069–$1,080) and GoodRx-discounted Mounjaro (~$900–$1,060). Mounjaro is FDA-approved for type 2 diabetes; using it for weight loss is off-label. Compounded tirzepatide is not FDA-approved. A licensed clinician determines what's appropriate. See Mounjaro cost without insurance.
Questions
Is compounded tirzepatide cheaper than Mounjaro?
Usually yes — flat compounded is about $186/month vs Mounjaro ~$900–$1,080/month cash-pay. Compounded tirzepatide is not FDA-approved, while Mounjaro is FDA-approved for type 2 diabetes. See NexLife pricing
Is Mounjaro approved for weight loss?
No — Mounjaro is FDA-approved for type 2 diabetes; using it for weight is off-label. The same molecule is FDA-approved for weight as Zepbound.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.